Skip to main content
Year archive

Evogene Ltd. — 2022 filings

All 164 regulatory filings released by Evogene Ltd. (EVGN) in 2022, sourced directly from the official regulator.

164 Filings
2022 Period
2022 filings (164)
Filing Released Lang
Biomica CEO to Attend the JP Morgan Healthcare Week in San Francisco between January 9-11, 2023
Regulatory Filings
2022-12-28 English
Biomica CEO to Attend the JP Morgan Healthcare Week in San Francisco between January 9-11, 2023
Report Publication Announcement
2022-12-28 English
Biomica Raises $20 Million in a Financing Round to Advance its Pipeline of Microbiome-based Therapeutics
Capital/Financing Update
2022-12-21 English
Biomica Raises $20 Million in a Financing Round to Advance its Pipeline of Microbiome-based Therapeutics
Report Publication Announcement
2022-12-21 English
6-K
Foreign Filer Report
2022-12-21 English
Receive $3.5 million Payment Related to Patent Portfolio under its Existing Seed Traits Collaboration with Bayer
Regulatory Filings
2022-12-08 English
Receive $3.5 million Payment Related to Patent Portfolio under its Existing Seed Traits Collaboration with Bayer
Report Publication Announcement
2022-12-08 English
6-K
Foreign Filer Report
2022-12-08 English
Evogene Reports Third Quarter 2022 Financial Results
Interim / Quarterly Report Q3 2022
2022-11-17 English
Evogene Reports Third Quarter 2022 Financial Results
Report Publication Announcement Q3 2022
2022-11-17 English
6-K
Foreign Filer Report
2022-11-17 English
Casterra Signs Royalty Agreement with Titan for Castor Oil Sales in South-Eastern Africa
Regulatory Filings
2022-11-15 English
Casterra Signs Royalty Agreement with Titan for Castor Oil Sales in South-Eastern Africa
Report Publication Announcement
2022-11-15 English
Biomica CEO to Participate in an Industry Panel Discussion at Microbiome Connect USA 2022 Summit
Regulatory Filings
2022-11-14 English
Biomica CEO to Participate in an Industry Panel Discussion at Microbiome Connect USA 2022 Summit
Report Publication Announcement
2022-11-14 English
Lavie Bio Investor Presentation
Investor Presentation
2022-11-14 English
Lavie Bio Investor Presentation
Report Publication Announcement
2022-11-14 English
6-K
Foreign Filer Report
2022-11-14 English
Changes in Management of Canonic
Board/Management Information
2022-11-10 English
Changes in Management of Canonic
Board/Management Information
2022-11-10 English
6-K
Foreign Filer Report
2022-11-10 English
Evogene Schedules Third Quarter of 2022 Financial Results Release & Conference Call for November 17, 2022
Report Publication Announcement
2022-11-07 English
Evogene Schedules Third Quarter of 2022 Financial Results Release & Conference Call for November 17, 2022
Report Publication Announcement
2022-11-07 English
Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification
Regulatory Filings
2022-11-03 English
Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification
Regulatory Filings
2022-11-03 English
6-K
Foreign Filer Report
2022-11-03 English
Lavie Bio Advances its Novel Bio-fungicide Program and Applies to the U.S. EPA for Regulatory Approval
Regulatory Filings
2022-10-12 English
Lavie Bio Advances its Novel Bio-fungicide Program and Applies to the U.S. EPA for Regulatory Approval
Report Publication Announcement
2022-10-12 English
6-K
Foreign Filer Report
2022-10-12 English
Evogene to Present at the LD Micro Main Event XV Investor Conference in Los Angeles
Regulatory Filings
2022-10-06 English
Evogene to Present at the LD Micro Main Event XV Investor Conference in Los Angeles
Regulatory Filings
2022-10-06 English
Canonic Launches its Second-Generation Medical Cannabis Products with High THC and Unique Terpene Profiles
Regulatory Filings
2022-09-21 English
Canonic Launches its Second-Generation Medical Cannabis Products with High THC and Unique Terpene Profiles
Report Publication Announcement
2022-09-21 English
6-K
Foreign Filer Report
2022-09-21 English
Results of 2022 Annual General Meeting
Declaration of Voting Results & Voting Rights Announcements
2022-09-16 English
Results of 2022 Annual General Meeting
AGM Information
2022-09-16 English
6-K
Foreign Filer Report
2022-09-15 English
Investor Presentation - September 2022
Investor Presentation
2022-09-15 English
Investor Presentation - September 2022
Investor Presentation
2022-09-15 English
6-K
Foreign Filer Report
2022-09-15 English
Lavie Bio Announces Appointment of Guri Oron as CEO
Board/Management Information
2022-09-14 English
Lavie Bio Announces Appointment of Guri Oron as CEO
Board/Management Information
2022-09-14 English
6K-changes in the management of its subsidiary, Lavie Bio Ltd
Board/Management Information
2022-09-14 English
6K-changes in the management of its subsidiary, Lavie Bio Ltd
Board/Management Information
2022-09-14 English
6-K
Foreign Filer Report
2022-09-14 English
Canonic Advances its Penetration into Europe by Signing its First Licensing Agreement with GroVida
Regulatory Filings
2022-09-13 English
Canonic Advances its Penetration into Europe by Signing its First Licensing Agreement with GroVida
Report Publication Announcement
2022-09-13 English
adjourned meeting annual meeting on September 15, 2022
AGM Information
2022-09-11 English
Adjournment of annual general meeting- will be reconvened on ,September 15, 2022
Regulatory Filings
2022-09-09 English
Adjournment of annual general meeting- will be reconvened on ,September 15, 2022
AGM Information
2022-09-09 English
6-K
Foreign Filer Report
2022-09-08 English
Unaudited Condensed Consolidated Financial Statements for the Six Months Ended June 30, 2022
Interim / Quarterly Report H1 2022
2022-09-07 English
Unaudited Condensed Consolidated Financial Statements for the Six Months Ended June 30, 2022
Report Publication Announcement H1 2022
2022-09-07 English
Evogene to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Investor Presentation
2022-09-07 English
Evogene to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Regulatory Filings
2022-09-07 English
6-K
Foreign Filer Report
2022-09-07 English
Immediate Report of Meeting to be held on September 8,2022' proxy
Proxy Solicitation & Information Statement
2022-09-05 English
Immediate Report of Meeting to be held on September 8,2022' proxy
AGM Information
2022-09-05 English
Immediate Report of Meeting to be held on September 8,2022' proxy
AGM Information
2022-09-05 English
Reports Second Quarter 2022 Financial Results
Earnings Release Q2 2022
2022-08-31 English
Reports Second Quarter 2022 Financial Results
Report Publication Announcement
2022-08-31 English
6-K
Foreign Filer Report
2022-08-31 English
Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
Regulatory Filings
2022-08-25 English
Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
Report Publication Announcement
2022-08-25 English
6-K
Foreign Filer Report
2022-08-25 English
ICL and Lavie Bio Enter Strategic Collaboration to Develop Novel Bio-Stimulant Products - ICL to invest $10 million in Lavie Bio
Regulatory Filings
2022-08-17 English
ICL and Lavie Bio Enter Strategic Collaboration to Develop Novel Bio-Stimulant Products - ICL to invest $10 million in Lavie Bio
Report Publication Announcement
2022-08-17 English
6-K
Foreign Filer Report
2022-08-16 English
Immediate Report of Meeting to be held on SEPTEMBER 8, 2022, Proxy statement
Proxy Solicitation & Information Statement
2022-08-03 English
Immediate Report of Meeting to be held on SEPTEMBER 8, 2022, Proxy statement
AGM Information
2022-08-03 English
Immediate Report of Meeting to be held on SEPTEMBER 8, 2022, Proxy statement
AGM Information
2022-08-03 English
6-K
Foreign Filer Report
2022-08-03 English
Evogene will release its financial results for the second quarter of 2022 on Wednesday, August 31, 2022, conference call on Wednesday, August 31, 2022, at 9:00 AM Eastern time, 4:00 PM Israel time
Earnings Release Q2 2022
2022-08-02 English
Evogene will release its financial results for the second quarter of 2022 on Wednesday, August 31, 2022, conference call on Wednesday, August 31, 2022, at 9:00 AM Eastern time, 4:00 PM Israel time
Report Publication Announcement
2022-08-02 English
Biomica Appoints Professor Gal Markel to Company’s Scientific Advisory Board
Board/Management Information
2022-07-28 English
Biomica Appoints Professor Gal Markel to Company’s Scientific Advisory Board
Report Publication Announcement
2022-07-28 English
Biomica Announces First Patient Dosed in its Phase I Study of its Microbiome-Based Immuno-Oncology Drug
Regulatory Filings
2022-07-26 English
Biomica Announces First Patient Dosed in its Phase I Study of its Microbiome-Based Immuno-Oncology Drug
Report Publication Announcement
2022-07-26 English
6-K
Foreign Filer Report
2022-07-26 English
Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification
Regulatory Filings
2022-07-14 English
Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification
Report Publication Announcement
2022-07-14 English
6-K
Foreign Filer Report
2022-07-14 English
Biomica Announces Successful Enrollment of First Patient in its Phase I Study of Microbiome-Based Immuno-Oncology Drug
Regulatory Filings
2022-07-11 English
Biomica Announces Successful Enrollment of First Patient in its Phase I Study of Microbiome-Based Immuno-Oncology Drug
Report Publication Announcement
2022-07-11 English
6-K
Foreign Filer Report
2022-07-11 English
Biomica to Present at the Microbiome Connect Europe 2022
Regulatory Filings
2022-07-05 English
Biomica to Present at the Microbiome Connect Europe 2022
Report Publication Announcement
2022-07-05 English
Biomica to Present at the 7th Microbiome Movement Drug Development Summit
Regulatory Filings
2022-06-15 English
Biomica to Present at the 7th Microbiome Movement Drug Development Summit
Report Publication Announcement
2022-06-15 English
6K-reports changes in its management
Board/Management Information
2022-05-31 English
6K-reports changes in its management
Board/Management Information
2022-05-31 English
6-K
Foreign Filer Report
2022-05-31 English
Evogene Reports First Quarter 2022 Financial Results
Earnings Release Q1 2022
2022-05-26 Hebrew (modern)
Evogene Reports First Quarter 2022 Financial Results
Report Publication Announcement
2022-05-26 English
Evogene Reports First Quarter 2022 Financial Results
Earnings Release Q1 2022
2022-05-26 English
Evogene Reports First Quarter 2022 Financial Results
Report Publication Announcement
2022-05-26 English
6-K
Foreign Filer Report
2022-05-26 English
Biomica to Present at the ASCO 2022 Annual Meeting
Regulatory Filings
2022-05-23 English
Biomica to Present at the ASCO 2022 Annual Meeting
Regulatory Filings
2022-05-23 English
Biomica to Present at the 2022 Digestive Disease Week (DDW) Conference
Regulatory Filings
2022-05-16 English
Biomica to Present at the 2022 Digestive Disease Week (DDW) Conference
Report Publication Announcement
2022-05-16 English
Other Report or Announcement
Regulatory Filings
2022-05-11 Hebrew (modern)
Other Report or Announcement
Report Publication Announcement
2022-05-11 English
Lavie Bio Announces Successful Product Launch of its BioInoculant result™ for the 2022 Spring Wheat Growing Season
Earnings Release FY 2022
2022-05-11 English
Lavie Bio Announces Successful Product Launch of its BioInoculant result™ for the 2022 Spring Wheat Growing Season
Report Publication Announcement
2022-05-11 English
release its financial results for the first quarter of 2022 and a a conference call on Thursday, May 26, 2022
Report Publication Announcement
2022-05-10 English
release its financial results for the first quarter of 2022 and a a conference call on Thursday, May 26, 2022
Report Publication Announcement
2022-05-10 English
AgPlenus Investor Presentation
Investor Presentation
2022-04-26 English
AgPlenus Investor Presentation
Investor Presentation
2022-04-26 English
6-K
Foreign Filer Report
2022-04-26 English
Biomica Announces Agreement with Sheba Medical Center for Joint Microbiome Clinical Research
Regulatory Filings
2022-04-13 English
Biomica Announces Agreement with Sheba Medical Center for Joint Microbiome Clinical Research
Report Publication Announcement
2022-04-13 English
Prospectus Supplement
Capital/Financing Update
2022-04-01 English
Prospectus Supplement
Report Publication Announcement
2022-04-01 English
20F FOR 2021
Annual Report FY 2021
2022-04-01 English
20F FOR 2021
Report Publication Announcement
2022-04-01 English
424B3
Prospectus
2022-03-31 English
20-F
Annual Report FY 2021
2022-03-31 English
6K-Changes in Management
Board/Management Information
2022-03-23 English
6K-Changes in Management
Board/Management Information
2022-03-23 English
6-K
Foreign Filer Report
2022-03-23 English
Evogene to Present at the Jefferies Virtual Synthetic Biology Week on March 23, 2022
Investor Presentation
2022-03-14 English
Evogene to Present at the Jefferies Virtual Synthetic Biology Week on March 23, 2022
Report Publication Announcement
2022-03-14 English
Evogene Reports Fourth Quarter and Full Year 2021 Financial Results
Earnings Release Q4 2021
2022-03-10 English
Evogene Reports Fourth Quarter and Full Year 2021 Financial Results
Report Publication Announcement
2022-03-10 English
6-K
Foreign Filer Report
2022-03-10 English
Evogene to Attend to World Agri-Tech Innovation Summit from March 22-23, 2022
Regulatory Filings
2022-03-07 English
Evogene to Attend to World Agri-Tech Innovation Summit from March 22-23, 2022
Report Publication Announcement
2022-03-07 English
Evogene to Attend ROTH Investor Conference - March 13-15, 2022
Investor Presentation
2022-03-03 English
Evogene to Attend ROTH Investor Conference - March 13-15, 2022
Report Publication Announcement
2022-03-03 English
Canonic Announces Professor Itamar Grotto Joining its Board of Directors
Board/Management Information
2022-02-16 English
Canonic Announces Professor Itamar Grotto Joining its Board of Directors
Board/Management Information
2022-02-16 English
Evogene Financial Results and Earnings Announcement Schedule for the Full Year and Fourth Quarter of 2021
Report Publication Announcement
2022-02-15 English
Evogene Financial Results and Earnings Announcement Schedule for the Full Year and Fourth Quarter of 2021
Earnings Release FY 2021
2022-02-15 English
FORM 6-K-Lavie bio -Investor presentation- February 2022
Investor Presentation
2022-02-14 English
FORM 6-K-Lavie bio -Investor presentation- February 2022
Investor Presentation
2022-02-14 English
6-K
Foreign Filer Report
2022-02-14 English
SCHEDULE 13G-Macquarie Group Limited
Major Shareholding Notification
2022-02-13 English
SCHEDULE 13G-Macquarie Group Limited
Regulatory Filings
2022-02-13 English
SC 13G/A
Major Shareholding Notification
2022-02-11 English
SCHEDULE 13G-ARK Investment Management LLC
Major Shareholding Notification
2022-02-10 English
SCHEDULE 13G-ARK Investment Management LLC
Regulatory Filings
2022-02-10 English
SC 13G/A
Major Shareholding Notification
2022-02-09 English
Evogene to Present at Aegis Virtual Conference
Report Publication Announcement
2022-02-07 English
Evogene to Present at Aegis Virtual Conference
Regulatory Filings
2022-02-07 English
Evogene reports changes in its management
Board/Management Information
2022-02-02 English
Evogene reports changes in its management
Board/Management Information
2022-02-02 English
6-K
Foreign Filer Report
2022-02-02 English
Announces Shipment of its Cannabis Varieties to Europe
Regulatory Filings
2022-01-31 English
Announces Shipment of its Cannabis Varieties to Europe
Report Publication Announcement
2022-01-31 English
Evogene to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022
Regulatory Filings
2022-01-19 English
Evogene to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022
Report Publication Announcement
2022-01-19 English
Canonic Announces Positive Results in Pre-Clinical Studies in its Precise Product Program for Medical Cannabis and Updated Canonic Investor Presentation
Investor Presentation
2022-01-18 English
Canonic Announces Positive Results in Pre-Clinical Studies in its Precise Product Program for Medical Cannabis and Updated Canonic Investor Presentation
Report Publication Announcement
2022-01-18 English
6-K
Foreign Filer Report
2022-01-18 English
Biomica Announces Clearance for First-in-Human Phase I Study of BMC-128 in Combination with Bristol Myers Squibb’s Anti-PD-1 Opdivo®
Regulatory Filings
2022-01-11 English
Biomica Announces Clearance for First-in-Human Phase I Study of BMC-128 in Combination with Bristol Myers Squibb’s Anti-PD-1 Opdivo®
Regulatory Filings
2022-01-11 English
6-K
Foreign Filer Report
2022-01-11 English
Biomica Investor Presentation
Investor Presentation
2022-01-10 English
Biomica Investor Presentation
Report Publication Announcement
2022-01-10 English
6-K
Foreign Filer Report
2022-01-10 English
Changes in Management
Board/Management Information
2022-01-03 English
Changes in Management
Board/Management Information
2022-01-03 English
6-K
Foreign Filer Report
2022-01-03 English